


a.) Amendment to the Claims

1. (Currently Amended) An orally administered pharmaceutical composition, comprising:

(a) (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione represented by the formula (I):



or a pharmaceutically acceptable salt thereof, and

(b) a selective serotonin reuptake inhibitor selected from the group consisting of paroxetine or a pharmaceutically acceptable salt and/or hydrate thereof, and fluoxetine or a pharmaceutically acceptable salt and/or hydrate thereof,

wherein a dose of said composition provides 0.0001-50 mg/kg of said (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione or said pharmaceutically acceptable salt thereof, and 0.001-1000 mg/kg of said serotonin reuptake inhibitor.

Claims 2-7 (Cancelled).

8. (Currently Amended) The pharmaceutical composition according to claim 1, wherein the pharmaceutically acceptable salt of paroxetine ~~selective serotonin reuptake inhibitor is paroxetine or fluoxetine, or is a hydrochloride and/or hydrate thereof.~~

9. (Previously Presented) The pharmaceutical composition according to claim 1, wherein the selective serotonin reuptake inhibitor is fluoxetine hydrochloride, paroxetine hydrochloride, or paroxetine hydrochloride hydrate.

Claims 10-52 (Cancelled).

53. (Previously Presented) The pharmaceutical composition according to claim 1, wherein a dose of said composition provides 0.001 to 30 mg/kg of said (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione, or said pharmaceutically acceptable salt thereof, and 0.005 to 1000 mg/kg of said serotonin reuptake inhibitor.

54. (Currently Amended) The pharmaceutical composition according to claim 53, wherein the pharmaceutically acceptable salt of paroxetine ~~serotonin reuptake inhibitor is peroxetine or fluoxetine, or is~~ a hydrochloride ~~and/or hydrate thereof~~.

55. (Currently Amended) The pharmaceutical composition according to claim 53, wherein the serotonin reuptake inhibitor is fluoxetine hydrochloride, paroxetine hydrochloride, or ~~peroxetine~~ paroxetine hydrochloride hydrate.

56. (Previously Presented) The pharmaceutical composition according to claim 1, wherein a dose of said composition provides 0.005 to 20 mg/kg of said (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione, or said pharmaceutically acceptable salt thereof, and 0.01 to 50 mg/kg of said serotonin reuptake inhibitor.

57. (Currently Amended) The pharmaceutical composition according to claim 56, wherein the pharmaceutically acceptable salt of serotonin reuptake inhibitor is ~~peroxetine~~ paroxetine or fluoxetine, ~~or is~~ a hydrochloride ~~and/or hydrate thereof~~.

58. (Currently Amended) The pharmaceutical composition according to claim 56, wherein the serotonin reuptake inhibitor is fluoxetine hydrochloride, ~~peroxetine~~ paroxetine hydrochloride, or ~~peroxetine~~ paroxetine hydrochloride hydrate.